Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SB's KYTRIL OVERTAKING GLAXO's ZOFRAN FOR CANCER CHEMO USE IN HOSPITALS AND CLINICS; GLAXO PRODUCT CONTINUES TO OUTSELL KYTRIL TWO-TO-ONE OVERALL

Executive Summary

SmithKline Beecham's Kytril (granisetron) is challenging Glaxo-Wellcome's Zofran (ondansetron) for leadership in the hospital and clinic chemotherapy submarket of the anti-nauseant category, SB Chairman Jan Leschly reported to a Bear Stearns investment seminar in New York on September 12.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028907

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel